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Summary
A first round of experiments conducted in 2003 and 2004 at CERN and at TRIUMF have
shown a significant enhancement of the biological effective dose ratio (BEDR) for antiprotons
compared to protons. The experimental methods and analysis as well as the definition of terms
used are described in the 2006 publication in Radiotherapy & Oncology (see appendix B). In
2006 the AD-4 collaboration conducted a set of experiments at higher beam energy and therefore
deeper penetration into the target. We also used for the first time a spread-out Bragg peak
(SOBP), as is standard in regular treatment situations. Early 2007 we performed a set of
irradiations using the same methods and materials at GSI with carbon ions giving the same
penetration depth and the same SOBP as the antiprotons at CERN. Due to problems with the a
priori estimate of dose in the case of antiprotons, a number of data points were rendered unusable
and the preliminary results presented in this report cannot be considered conclusive. This leads us
to the request for another period of beam time in which we will increase the efforts on dosimetry
and beam development prior to the biological measurements. The data taken at GSI used a beam
of clinical quality with excellent absolute dosimetry available and these data are in excellent
agreement with other studies on biological effects of carbon ion.
Parallel to the biological measurements with antiprotons we performed several
experiments aimed at improving the dosimetry of the antiproton beam. Two problems needed to
be overcome. Not only is the response to high LET radiation for most dosimeters not well
understood, but in addition, the pulsed time structure of the beam makes the instantaneous dose
rate too high for most standard dosimeters to handle. We used Alanine tablets and ionization
chambers to measure the response to the antiproton beam and then compared these results to
predictions using different Monte Carlo calculations. We found good agreement between the code
package FLUKA and the measurements using both types of detectors and feel confident that we
can estimate absolute dose within 10 to 20% in future experiments.
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I. Biological Measurements:
In October 2006 we performed our first studies of cell survival using a 502 MeV/c
antiproton beam from the AD. This beam energy allowed a penetration into our target of
approximately 10 cm and much more closely resembled possible therapeutic situations.
In addition we used a set of passive degraders to generate a spread-out Bragg peak of 10
mm depth, irradiating a volume of approximately 300 mm3. The dose-depth profile for
both antiprotons and carbon ions are shown in figure 1.
Fig. 1: Relative dose for carbon ions and antiprotons vs. depth in the target.
Within the maximum allowable time for a single set of biological measurements,
dictated by the overall survival time of the cell cultures from harvesting to analyzing, we
performed 4 different irradiations with nominal dose values of 0.25, 0.5, 1, and 5 Gy.
Preliminary analyses of the antiproton data showed that our estimate of deposited dose
was based on a faulty value of the beam diameter and that a number of data points were
unusable. This was caused by the fact that we had to rely on the beam diameter value
obtained from a fit to the read-out of the last wire chamber in the DEM line. Due to the
course grid of this chamber and a suspected bug in the fitting software the beam diameter
was overestimated by a factor of 1.7 and the dose therefore underestimated by a factor of
2.9. This error not only caused a complete overkill in the nominal 5 Gy run, but also
limited us to the 4 measurements within the allowable time frame. The actual total dose
delivered during this set was 20 Gy and would have allowed us to collect meaningful data
for at least twice as many points below the 5 Gy value. Figure 2 below shows the raw
data on cell survival vs. depth obtained in this experiment (note the sharp rise in cell kill
with depth near the Bragg peak).
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Fig. 2: Survival fraction vs. depth in the target for V79 Chinese Hamster cells irradiated with
antiprotons. The dose values used as labels are estimated from FLUKA calculations using the
number of antiprotons delivered and the radial beam profile obtained from radiochromic film
irradiated simultaneously with the cell samples and analyzed after the run.
In early 2007 we conducted an experiment using carbon ions at GSI. Here a beam of
clinical quality and absolute dosimetry is available. We performed survival
measurements on 8 samples with plateau dose values between 0.3 and 4.0 Gy. Survival
data vs. depth are shown in figure 3.
Figure 3: Survival fraction vs. depth in the target for V79 Chinese Hamster cells irradiated with
carbon ions
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The cell kill in the plateau region is noticeable higher for carbon ions than for
antiprotons at similar plateau dose. This is due to the elevated RBE of carbon ions
already in the entrance channel. Also noticeable is the earlier and more gradual increase
of cell kill for carbon ions compared to antiprotons.
Figure 4 shows the results of our analysis for the carbon ion experiment. Defining the
plateau as data points 1 and 2 and the peak as points 9 – 14 of the depth survival curve we
can plot survival vs. absolute dose for peak and plateau. In addition we plot survival vs.
dose for a reference X-ray source with low LET and RBE of 1. Using a survival rate of
10% we extract the RBE0.1 for carbon ions as 1.38 in the plateau and 2.17 in the peak.
Figure 4: Survival fraction vs. absolute for V79 Chinese Hamster cells irradiated with carbon ions.
By comparing the dose needed to achieve a survival of 10% using low LET X-rays to the dose
needed when using carbon ions we extract a relative biological efficiency of 1.38 in the plateau
and 2.17 in the peak.
Figure 5 shows the same analysis for the antiproton runs. Here the plateau is defined
as points 1 – 4 (due to the poorer statistics and the weaker incline with depth we chose
more points than in the carbon case) and the peak as points 1 – 13. Varying these choices
by a few points did not significantly affect the outcome. Within the limits of the statistical
quality of the data points and the uncertainty of absolute dose estimation (using FLUKA
together with the number of antiprotons delivered from the AD to the DEM line and the
beam profile as measured with the radiochromic film) we reach the preliminary
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conclusion that the RBE in the plateau region of antiprotons is consistent with the value
of 1 as normally used for protons in radiotherapy planning and that the RBE averaged
over the SOBP is 1.54. If more data points are obtained in the plateau region we could
cross check the dose estimation assuming that the antiproton RBE for plateau is equal for
protons and antiprotons. Also, a few more points in the peak at intermediate dose would
lend more significance to the fit of the survival curve to the data.
Fig. 5: Survival vs. dose for Chinese Hamster cells irradiated with an antiproton beam of 502
MeV/c energy at the DEM line.
The preliminary analysis shown here continues to support the radiobiological interest
in antiproton beams, but a more complete data set is necessary to validate these findings
and produce better quantitative results.
II. Dosimetry Studies:
To interpret a measured response of a biological system exposed to a beam of hadrons
in terms of dose deposition, knowledge of the Relative Biological Effectiveness (RBE)
for the particular beam of particles is necessary. Similarly, for a radiation detector the
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relative effectiveness (RE) is relating the observed detector response with dose
deposition.
Attempts to measure the RBE directly in the peak region of an antiproton beam so far
have been problematic, since dosimetry of the antiproton depth dose curve is difficult due
to the unknown dosimeter response. Ionization chambers behave non-linear due to
volume recombination arising from the pulsed nature of the antiproton beam available at
CERN. Measurements using Boag’s theorem correcting for recombination effects have
been performed during the October 2007 run and a publication on this is in preparation.
(see appendix C for a preliminary draft of this paper).
We also performed a set of measurements with Alanine detectors and compared the
results with simulations using the particle energy spectrum calculated by FLUKA, and
using the track structure model of Hansen et Olsen for conversion of calculated dose into
response. Good agreement was observed between the measured and calculated relative
effectiveness although a slight underestimation of the calculated values in the Bragg peak
remains unexplained. The model prediction of response of alanine towards heavy charged
particles encourages future use of the alanine detectors for dosimetry of mixed radiation
fields. (see appendix D for a draft of this paper to be submitted).
III. Beam Time Request:
To augment the existing data and to allow a full analysis of our data as needed for a
publication of this work in a radiobiological journal we plan to perform a second set of
irradiations with the same beam energy. Besides filling in missing data points it will also
constitute a repeat measurement, which is considered a standard requirement in biological
measurements as results can depend on many environmental parameters.
We plan to do a full dosimetric study of the beam prior to the irradiation of any
biological samples using data from our ionization chambers, radiochromic film samples,
beam current monitors in the AD and at the exit of the DEM line. This will require
approximately 48 hours of beamtime, allowing some time for the initial beam
development work to be performed by the CERN team. Past experience has shown that
this is a critical step in the experimental cycle and cannot be underestimated.
The actual irradiation work then must be completed within a 36 hour time frame for a
single set of measurements. If time permits (assuming a smooth operation of the
accelerator) we would also like to perform a set of irradiations of human cells, as
performed last October, to finish these measurements through a biological control
measurement. At this time we are analyzing the data from last October as we needed to
wait for the results of the cell survival measurements to decide on the exact analysis
protocol. These data will be available prior to October and will allow us to define and
decide on the details of this irradiation. Due to the same constraints on sample lifetime,
this will also be restricted to 36 hours maximum.
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The overall program can be completed in one week of running. In order to impact the
other experiments as minimal as possible we request to be granted the last week of
running time at the AD as last year. With the biological preparations necessary and
considering the limited survival time of the samples once the cells have been harvested
and embedded in gelatin, a precise schedule must be established early on. The actual
irradiation time can then be adjusted by a few days within the week by waiting until the
beam development is completed and dosimetry has been fully established before
preparing the actual samples from cell cultures started a few weeks beforehand.
Any limited down time between experiments can be used beneficially to continue our
studies on dosimetry issues.
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Appendix B:AntiprotonsThe biological effectiveness of antiproton irradiation
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Background and purpose: Antiprotons travel through tissue in a manner similar to that for protons until they reach the
end of their range where they annihilate and deposit additional energy. This makes them potentially interesting for
radiotherapy. The aim of this study was to conduct the first ever measurements of the biological effectiveness of
antiprotons.
Materials and methods: V79 cells were suspended in a semi-solid matrix and irradiated with 46.7 MeV antiprotons,
48 MeV protons, or 60Co c-rays. Clonogenic survival was determined as a function of depth along the particle beams. Dose
and particle fluence response relationships were constructed from data in the plateau and Bragg peak regions of the
beams and used to assess the biological effectiveness.
Results: Due to uncertainties in antiproton dosimetry we defined a new term, called the biologically effective dose
ratio (BEDR), which compares the response in a minimally spread out Bragg peak (SOBP) to that in the plateau as a
function of particle fluence. This value was 3.75 times larger for antiprotons than for protons. This increase arises due
to the increased dose deposited in the Bragg peak by annihilation and because this dose has a higher relative biological
effectiveness (RBE).
Conclusion: We have produced the first measurements of the biological consequences of antiproton irradiation. These
data substantiate theoretical predictions of the biological effects of antiproton annihilation within the Bragg peak, and
suggest antiprotons warrant further investigation.c 2006 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 81 (2006) 233–242.
Keywords: Antiproton; RBE; Particle irradiation; High LETFor conventional photon irradiation, the maximum dose
that can be delivered to a tumor is limited by the tolerance
of irradiated adjacent normal tissues. Several technological
improvements in radiation delivery, including intensity-
modulated radiotherapy (IMRT), have made it possible to
confine the high-dose region to almost any target volume
of interest and thus reduce the dose to adjacent tissues
[1–3]. However, even with these techniques, normal tissue
tolerances can prevent delivery of a dose sufficient to
achieve tumor cure. IMRT also results in a larger total body0167-8140/$ - see front matter c 2006 Elsevier Ireland Ltd. All rights reexposure and thus an increased risk of secondary cancers
[4]. For many types of tumors, this has led to unacceptably
low tumor control probability (TCP) and to high levels of
morbidity. An alternative approach involves the use of pro-
tons and other heavier ions [5–8]. For these charged parti-
cles, both the amount and rate of energy deposition
increase dramatically as the particle nears the end of its
range. This results in a large enhancement in absorbed dose
at a precise depth in tissue (the Bragg peak) compared with
the dose deposited at the entrance to the body (theserved. doi:10.1016/j.radonc.2006.09.012
1 BERGOZ Instrumentation, Espace Allondon Ouest, 06130 Saint
Genis Pouilly, France.
234 Antiproton radiobiologyplateau). For treatment purposes, the position of the Bragg
peak needs to be spread out to cover the tumor volume and
the production of such a spread-out Bragg peak (SOBP)
results in a build up of plateau dose and hence a reduction
in the ratio of dose in the SOBP relative to the plateau. How-
ever, in contrast to photons, the dose in the SOBP that cov-
ers the tumor volume remains larger than that in the normal
tissue entrance region. High linear energy transfer (LET)
particles such as carbon ions also produce a much higher
ionization density in the Bragg peak region and consequently
an increase in the relative biological effectiveness (RBE) of
the dose deposited in the tumor [9–11]. This provides a po-
tential further therapeutic advantage, especially for tumors
that have a large hypoxic fraction or for those that are
resistant to conventional radiation [12]. Furthermore, since
very little dose is deposited distal to the Bragg peak,
charged particles are ideally suited for treatments of
tumors close to radiosensitive regions. These favorable
physical and biological characteristics have led to recent
developments of proton and heavy ion cancer therapy cen-
ters worldwide.
Conversion of the mass of a proton–antiproton pair dur-
ing annihilation constitutes the highest density energy
source currently available. This has led to a number of pro-
posals for practical applications of antiprotons, including
radiotherapy, which is feasible with current antiproton pro-
duction technology [13]. Like other charged particles, anti-
protons deposit most of their kinetic energy near the end of
their path in the Bragg peak. In addition, as an antiproton
comes to rest it annihilates, depositing additional energy
in the form of particles that may have a significantly
enhanced biological effectiveness [14]. The majority of
the total annihilation energy of 1.88 GeV is carried away
by high-energy pions, neutrons and c-rays. We have estimat-
ed (unpublished data) that the dose deposition from these
particles is of a similar magnitude to that reported for a pas-
sively degraded proton beam [4]. However, at the Bragg
peak it has been estimated that antiprotons deposit an addi-
tional 30 MeV within a few millimeters of the annihilation
vertex [15]. The only experimental data relevant to the
application of antiprotons for biological purposes were pro-
duced by Sullivan [16], who measured the relative physical
dose deposition in the plateau and the Bragg peak regions
for antiprotons at the low energy antiproton ring (LEAR) at
CERN. He found that although the additional local dose
deposited is small compared to the total annihilation ener-
gy, it does represent an approximate doubling of the physi-
cal dose deposited per particle in the Bragg peak compared
to protons. Furthermore, the RBE of this additional dose is
likely to be significantly higher than that for protons be-
cause it is due partly to recoiling heavy fragments produced
in the annihilation event with short range and high LET. The
remainder of the annihilation energy that is carried
away,outside of the body, could potentially be used for
real-time imaging of the dose distribution.
To date there has been no attempt to assess the biolog-
ical effects of antiprotons. This stimulated us to initiate an
experiment, AD-4/ACE [17,18], running at the antiproton
decelerator (AD) at CERN, to measure the biological effects
of antiproton irradiation and compare it to the results
achievable with protons.Materials and methods
Beam characteristics
The AD at CERN delivered a 200–500 ns beam pulse con-
taining approximately 3 · 107 antiprotons every 85 s. For our
experiment the extraction energy was 46.7 MeV. In order to
spread the Bragg peak we used a ridge filter consisting of a
plastic sheet machined with a matrix of pixels 1 mm2 in
area. Three pixel thicknesses (1, 1.8 and 2.6 mm) were used
at a ratio of 41:31:28 to create a SOBP as smooth as possible
over a distance of slightly more than 2.5 mm. The degrader
was placed 25 cm upstream of the target so that the lateral
straggling together with the free drift in air would remove
any radial dose inhomogeneity from the degrader in the
samples. A schematic of the set-up is shown in Fig. 1.
For proton irradiation, we utilized the treatment facility
located at TRIUMF, details of which have been previously
published [19]. The energy was reduced to 48 MeV with a
range shifter to closely match the energy of the antiproton
beam. The proton Bragg peak was also spread out over an
area slightly larger than 2.5 mm using a two-step rotating
wedge filter in order to create a dose profile which matched
that of the antiproton as close as possible.
For 60Co irradiation, a Theratron unit at the Vancouver
Cancer Centre was used as described previously [19].
Dosimetry
Due to the pulsed nature of the antiproton beam it was
not possible to use currently available dosimetry equipment
to measure absorbed dose. The large number of antiprotons
delivered in such a short period of time leads to saturation,
non-linearity and unreliability of conventional equipment
such as ionization chambers. Thus, in order to estimate
the absorbed dose and the relative depth dose profile we
carried out a Monte Carlo simulation based on measure-
ments of antiproton fluence using the MCNPX code [20].
Antiproton fluence was monitored using two independent
methods. After the ridge filter the antiproton beam passed
through a current monitor (Bergoz1 BCM/ICT) capable of
integrating a pulse with rise times as short as a few picosec-
onds without significant loss. The voltage was then held
level for about 400 ls for read-out. The signal processor
used two integrating windows to correct for baseline noise
and therefore achieved high accuracy for low beam current.
In our set-up the sensitivity was 1 mV/6.3 · 105 antiprotons,
resulting in a typical read-out of 50 mV per pulse. The noise
was less than 5 mV, allowing a fluence measurement to
within 10%. We also received a signature from the acceler-
ator on the number of antiprotons having left the ring upon
ejection, which was typically within 20% of the ICT mea-
surement indicating a high-transfer efficiency to our
experiment.
In order to estimate the dose with Monte Carlo methods,
it was also necessary to determine the radial-beam profile,
and thus the fraction of antiprotons that enter the biologi-
cal sample. We monitored the integrated beam profile using
GAF chromic film, which darkens in a linear way with dose.
Because the sensitivity is low, it was necessary to integrate
Fig. 1. Schematic set-up of the antiproton experiment. The antiproton beam leaves the accelerator vacuum through a thin titanium window,
passes through a two-step ridge filter, a beam current monitor and a scintillator before entering a plexiglass tank containing a glycol/water
mixture and the biological sample (see photo inset upper right). Also shown are the antiproton dose profile and the slicing protocol for
extracting cell survival data after the irradiation.
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system consisting of a thin sheet of BC-400 scintillator
material intercepting the beam without affecting energy
or straggling significantly. This material was placed near
the entrance to the phantom and viewed by a sensitive
CCD camera.2 To reduce noise, the camera was synchro-
nized with the arrival of the pulse, and the signal was suffi-
cient to obtain the beam profile and to determine the
centroid and diameter of a single shot from the AD. This
system also allowed us to adjust the beam position in sub-
millimeter increments. Only the central part of the Gauss-
ian-shaped beam was used to ensure a radial variation of
less than 5%.
For protons, the delivered dose was measured by a cali-
brated transmission chamber and relative depth–dose mea-
surements were carried out with a parallel plate ionization
chamber.2 APOGEE Instruments Inc., KX1E Digital Imaging System, com-
prising a TE cooled camera head with Grade 2 Kodak KAF-0401E
CCD.Measurement of clonogenic survival
We chose to use V79-WNRE cells in these studies because
this cell line has been used previously to quantify the biolog-
ical characteristics of other particle beams [19]. We em-
ployed a modified form of the sliced-gel technique of
Skarsgard and co-workers [19,21] coupledwith the cell sorter
survival assay, details of which are published elsewhere
[19,22]. Briefly, cells were cultured in MEM supplemented
with 10% fetal bovine serum and maintained in exponential
growth. Cells were harvested with trypsin, and re-suspended
at 2 · 106 cells/ml in MEM containing 20% FBS and 12% gelatin
(gel/medium). At 37 C, this was a viscous fluid and for proton
and antiproton irradiations, was poured into ABS (acryloni-
trile butadiene styrene) plastic tubes of 0.6 cm inside diame-
ter and 18 cm length, with a piston located so as to
accommodate a 6-cm deep cylinder of gel/medium. For
60Co irradiation, 0.5–1 ml samples of the cell/gel suspension
were deposited into 5 ml plastic test tubes. After solidifica-
tion at 4 C the tubes were sealed and stored on ice.
For irradiation, sample tubes were placed with their axis
collinear with the beam axis, in a circulating, refrigerated
bath containing a 19.3% glycerol/water solution. The
236 Antiproton radiobiologydensities of materials encountered by the beam (ABS tube,
gel/medium, glycerol/water) were carefully chosen to
produce identical stopping powers throughout the entire
phantom. The cells were maintained at 2 C throughout
the irradiation procedure and were kept on ice prior and
subsequent to irradiation. This maintained the spatial
organization of the cells, and also avoided dose-rate effects
that would have otherwise confounded measurements (indi-
vidual sample antiproton exposures were as long as 16 h).
Only the central part of the antiproton beam was used to
irradiate the cell sample tube, thus assuring an intensity
variation across the sample of less than 5%. After irradia-
tion, the gel was extruded from the tube and cut into slices
of 0.5 or 1 mm thickness. These slices were melted in warm
culture medium and a cell sorter was then used to sort an
accurately known number of cells from each sample. Two
to three sorts from each slice were plated into individual
100-mm Petri dishes with 14 ml of culture media and
allowed to form colonies (defined as >50 cells) for 6–7 days.
A sufficient number of cells was plated to produce 400–
500 colonies per dish. Three slices upstream of the SOBP
which received zero primary dose were used to measure
the plating efficiency (PE).
For comparison purposes we alsomeasured the clonogenic
survival response of V79 cells in the gelatin-matrix to 60Co
irradiation. This served as both a reference to measure the
RBE for protons and also allowed us to control for any minor
variations in the radiosensitivity of the cells between exper-
iments. For antiproton experiments, samples were prepared
at CERN and irradiated in Vancouver after transport. For pro-
ton experiments, 60Co samples were irradiated at times
similar to the proton samples.
Determination of RBE and BEDR
The goal of our experiments was to obtain an estimate of
the biological effect of antiprotons. Conventionally, this
property would be the RBE, which is equal to the ratio of
absorbed dose between the conventional and test irradia-
tion producing the same level of survival. For proton irradi-
ation it was possible to determine RBE because we have a
reliable measure of dose. RBE was calculated as the ratio
of 60Co to proton doses which resulted in the same level
of cell survival. Dose values were determined from linear
quadratic (LQ) fits to the survival data.
It was not possible to calculate a similar RBE for antipro-
tons because we did not have a reliable measure of the
absorbed dose. Thus, it was necessary to design compara-
tive experiments in such a way that measurement of abso-
lute dose was not required. To do this we compared
survival responses obtained in the SOBP with those obtained
in the plateau following delivery of a known number of par-
ticles (fluence). Because the dose in the plateau and the
SOBP are directly proportional to the fluence, it is possible
to compare the responses without knowing the conversion
factor from fluence to dose. We defined a new term called
the biologically effective dose ratio (BEDR), equal to the ra-
tio of plateau to SOBP fluences required to produce a de-
fined level of survival.
BEDR ¼ Fluenceplateau
Fluencepeak
;where Fluenceplateau and Fluencepeak are the different flu-
ences that produce the same level of cell survival. It can
be shown that BEDR is numerically equal to
BEDR ¼ F RBEpeak
RBEplateau
;
where F is the ratio of the physical dose deposited in the
SOBP to that deposited in the plateau.Results
Physical dose
The axial physical dose profiles of the proton and anti-
proton beams are shown in Fig. 2. For protons, this figure
represents the measured relative dose as a function of
depth in water and for antiprotons it is a Monte Carlo esti-
mate based on conversion from particle fluence measure-
ments. The modulation of dose in the Bragg peak results
from the use of the discrete two-step degrader with a step
size comparable to the width of the pristine Bragg peak for
this energy. As expected, the peak to plateau dose ratio is
much larger for antiprotons than for protons. Defining a
point 7 mm upstream as the plateau yields a measured
dose ratio of 2.0 for protons and an estimated 4.0 for anti-
protons. The positions and widths of gel slices used to
measure clonogenic survival in different regions of the
beam are also shown.
Because samples were irradiated over a 24-h period at
CERN and then transported to Vancouver, the cells were
maintained in gel at cold temperatures for 42–54 h. The
PE measured from each sample tube, as well as the PE from
several unirradiated controls allowed us to monitor the con-
sequences of this exposure (see Fig. 3a). Although, there
was a small trend towards increased toxicity with time (a
drop in PE from 0.7–0.6), the PE remained high through-
out the experiment and comparable to that measured previ-
ously[19]. Fig. 3b shows the 60Co survival curves determined
during both the proton experiment at TRIUMF and the anti-
proton experiment in CERN. The similarity of these two
responses also indicates that the long exposure to gel did
not significantly affect radiosensitivity.
Survival data
Fig. 4a and b show the clonogenic survival determined
from individual gel slices plotted as a function of depth
throughout the proton and antiproton beams. The depth in
gel has been converted to its stopping-power equivalent
depth in water. All material in front of the gel (the gel
cap, tank window, and other materials) has also been con-
verted to water equivalent depth and included so that the
plots represent the total particle range.
For the proton experiment, cell survival was determined
from 20 individual slices as a function of depth in each of
eight sample tubes receiving a different dose to the SOBP.
The dose range to the SOBP was 1–14Gy and resulted in sur-
vival measurements over 1 log in both the peak and plateau
regions. The survival responses are in good agreement with
expectations from the measured dose distributions shown in
the upper panel. The steep dose gradient beyond the edge
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Fig. 2. Physical dose profiles and slicing protocol. The measured physical dose along the axis of the range-modulated proton beam at TRIUMF
(a) and the Monte Carlo estimated physical dose along the axis of the range-modulated antiproton beam at CERN (b) are shown as a function of
depth in water. The SOBP is approximately 2.5 mm in width. Also plotted are the positions and widths of gel slices from which clonogenic
survival was determined. Four positions in the peak (2 mm total width), and two positions 7 mm upstream from the peak center (2 mm total
width) were used to determine average values for the SOBP and plateau, respectively (shaded areas). Three slices beyond the Bragg peak were
used to determine plating efficiency.
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Fig. 3. Plating efficiency and radiosensitivity during extended exposure to gelatin. The plating efficiency of V79-WNRE cells as a function of
time at 0 C in the gelatin matrix from samples used during one of the antiproton experiments (a). Plating efficiency was determined from
individual sample tubes that received antiproton irradiation (p), or from untreated control tubes (control). Plating efficiencies of the 60Co
control samples are also shown (60Co). The clonogenic survival of V79-WNRE cells is shown as a function of 60Co dose (b). These 60Co-response
curves were derived from samples prepared during the antiproton experiment at CERN (p) and during the proton experiment at TRIUMF (p+).
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ple tube to less than 0.5 mm.
Fig. 4b shows similar data obtained following irradiation
with antiprotons. Because it was not possible to measure
absolute dose, we used the estimates based on measured
antiproton fluence and Monte Carlo models. Survival data
were determined at 23 positions in depth for six individual
sample tubes irradiated with estimated peak doses between
1 and 25Gy. These data demonstrate a much higher differ-
ence between the peak and plateau regions. Interestingly,the non-uniform dose in the SOBP predicted by Monte Carlo
analysis is reflected in these measurements.
RBE and BEDR
In Fig. 5a, we have plotted the survival as a function of
absorbed dose for both proton and 60Co irradiation. The pro-
ton dose responses were constructed from the data shown in
Fig. 4a. The survival in the peak region was calculated from
the average of the four 0.5 mm slices located within the
SOBP and the survival in the plateau was calculated as the





































































Fig. 4. Clonogenic survival response to antiprotons and protons. The clonogenic survival of V79-WNRE cells is plotted as a function of water
equivalent depth along the axis of the proton beam (a) and antiproton beam (b). Survival was measured in 20 individual gel slices after proton
irradiation and in 23 slices after antiproton irradiation in individual tubes irradiated with a range of peak doses. Each line represents a single
tube irradiated with the measured proton (a) or estimated antiproton (b) dose to the SOBP. For reference, the physical dose profiles are shown
in the upper frames.
238 Antiproton radiobiologyaverage of two 1 mm slices located 7 mm upstream (see also
Fig. 2a). The relative dose in the plateau at this point was
51% of that in the peak. The resulting dose response in
the plateau is indistinguishable from that for 60Co irradia-
tion, and thus the RBE in this region is 1. The radiation sen-
sitivity of cells irradiated in the SOBP is significantly higher.
We used the LQ model to fit the 60Co and proton SOBP
responses and then calculated the RBE at different levels
of survival (Fig. 5a). The RBE20 (RBE at a surviving fraction
of 20%) for the proton SOBP is equal to 1.2, in good agree-
ment with previous measurements with this system [19].
In Fig. 5b and c, we have replotted the plateau and SOBP
survival as a function of particle fluence rather than
absorbed dose. In this manner, the response in the SOBP
appears far more sensitive than in the plateau (compare
proton data in Fig. 5a and b). This arises because the
absorbed dose per particle in the SOBP is higher (for protons
2-fold) and additionally because the RBE in the SOPB is
higher. These fluence based survival responses were then
fit using the LQ equation, and the resulting parameters used
to calculate the BEDR. This value is equal to the ratio of flu-
ences in the plateau and the peak that give the same level
of cell survival. At 20% survival the BEDR for protons is 2.4.
The survival responses in the SOBP and plateau regions of
the antiproton beam are shown as a function of fluence in
Fig. 5c. These plateau data were calculated as the average
survival from two 1 mm slices located 7 mm upstream of the
SOBP, and the SOBP response is taken from the average of
the four 0.5 mm slices located within the SOBP region. Data
extracted from the data set shown in Fig. 4b are labeled as
Exp1. Also shown in Fig. 5c, are data obtained from a small-er experiment carried out 3 months prior (Exp 2). The BEDR
for antiprotons determined from LQ fits to these data is
shown in the lower frame of Fig. 5c. At 20% survival the anti-
proton BEDR is equal to 9.0, or about 3.75 times higher than
for protons.
Antiproton RBE
Although, we could not directly measure antiproton RBE,
it is possible to make an estimate of this value based on the
measurements presented so far. The ratio of BEDR for anti-


















The only value in this equation that has not been estimated
or measured is the antiproton RBE in the plateau. However,
this value is equivalent to the proton plateau RBE provided
that in-fight annihilation dose is insignificant. We estimated
the consequence of in-flight annihilation by finding an accu-
rate universal fit to all measured annihilation cross sections
known to us, from which we calculated the effect in our
specific case [23]. Using our knowledge of the stopping
power of antiprotons we then calculated the number of
remaining antiprotons, and the electronic energy deposited
along the beam path (Fig. 6a). Here, we have ignored elastic
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Fig. 5. Determination of RBE and BEDR. The average survival of cells within the SOBP and plateau region of the proton beam are plotted as a
function of absorbed dose (a, upper frame). These data were fit with the LQ model, and the resulting parameters used to calculate the RBE as a
function of surviving fraction (a, lower frame). In (b), the same proton data from (a) are plotted as a function of proton fluence (upper frame)
and fits to these data were used to calculate the BEDR (lower frame). In (c, upper frame), the average survival of cells within the SOBP and
plateau region of the antiproton beam are plotted as a function of antiproton fluence. Fits to these data were used to calculate the antiproton
BEDR (c, lower frame). In the text, BEDR and RBE values are quoted at a survival of 20%. At this level of survival, the BEDR for antiprotons is
approximately 3.75-fold higher than for protons due to the increased annihilation dose in the SOBP and its higher RBE.
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Fig. 6. Estimation of RBE in the antiproton SOBP. The amount of deposited energy along the tracks of 50, 120 and 250 MeV antiprotons passing
through water (dashed lines) (a). Also shown in this plot are the remaining fractions of antiprotons for each of these energies (solid curves). In
(b) the RBE in the antiproton SOBP has been estimated for different values of the peak to plateau dose ratio. The product of the RBE and this
ratio is equal to the measured BEDR. The shaded area represents the best estimate for the dose ratio.
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sumed that each annihilation deposits 30 MeV of energy
locally. The loss of antiprotons with an initial energy of50 MeV due to in-flight annihilation is very small (8%) and
even for higher energies up to a depth of 40 cm, a distinct
Bragg peak remains.
240 Antiproton radiobiologyThus, if we assume equivalent plateau RBE values, the







The only value that has not been directly measured in this
equation is the dose ratio (F) for antiprotons. However, if
we use the Monte Carlo estimate of 4.0 for this value as
depicted in Fig. 2b, the antiproton RBE in the SOBP is equal
to 2.25. Because we are not completely certain of the Monte
Carlo dose estimates we have also plotted in Fig. 6b the
relationship between F and the peak RBE for antiprotons
that is required to produce the measured BEDR20 value of
9.0.Discussion
The biological effectiveness of antiprotons
The data presented here are the first measurements to
date of the biological consequences of antiproton irradia-
tion. The nature of the antiproton beam made it impossible
to determine standard dose–response curves that could be
compared with low-LET radiation to determine the RBE. We
thus defined the BEDR, a new term that is based on compar-
ing the responses in the peak and plateau regions as a
function of particle fluence. This value is biologically mean-
ingful, because it represents a direct measurement of the
gain in ‘biologically equivalent dose’ deposited in the Bragg
peak region compared to that in the plateau. Since the dose
deposition in the plateau is essentially identical for proton
and antiproton beams of similar energy, a comparison of
the BEDR of protons with that of antiprotons provides a di-
rect measure of the additional biological consequences of
annihilation events at the Bragg peak.
At 20% survival the BEDR20 for antiprotons was equal to
9.0 and for protons it was 2.4- or 3.75-fold lower. The
BEDR for antiprotons increased because of two factors:
(i) the increase in the ratio of dose deposited in the SOBP
relative to the plateau due to the annihilation dose and (ii)
the increase in the RBE of the extra annihilation dose. For
protons, the RBE in the SOBP was 1.2 and the peak to pla-
teau dose ratio was 2.0. The product of these two values
gives the BEDR value of 2.4. For antiprotons our best esti-
mate of the peak to plateau dose ratio is 4.0-, or 2-fold
higher than that for protons. This results in an estimate
of the antiproton SOBP RBE of approximately 2.25 provided
that the RBE in the plateau region is similar to that for
protons. Our estimation of in-flight annihilation dose indi-
cates that this effect is indeed small, suggesting that this
assumption is valid. Given the fact that the annihilation
dose in the peak accounts for only an estimated 50% of
the total dose in this area, an average RBE of 2.25 in this
region implies that the RBE for the dose contributed by
annihilation must be very high.
Comparison to carbon ions
It would be interesting to compare our measurements
with other high LET particles, such as carbon ions. Blakely
et al. [9] measured cell survival in pristine peaks of400 MeV/u carbon ions using the Berkeley Bevalac. Range
straggling in this high-energy beam yielded a Bragg peak
of stopping width similar to our modulated proton and anti-
proton beams (3 mm at 80% of maximum). We estimated
the BEDR for this carbon ion beam to be 7.9, using a defini-
tion for the plateau point reflecting the situation encoun-
tered at CERN (7 mm upstream). However, the much
greater range of the carbon ions adds uncertainty to this
estimate. Because the gradient on the proximal side of
the Bragg peak changes drastically with penetration depth,
it is difficult to make a proper choice for the plateau defini-
tion. Weyrather et al. [10,11] have also reported RBE values
for a range of carbon ion energies. Using SRIM [24] we calcu-
lated a dose profile for a pristine carbon beam with a range
equivalent to our set-up at CERN and estimated the maxi-
mum BEDR from the Weyrather data to be 8.5 (after cor-
recting for the loss of primary ions due to fragmentation).
This result is for an unmodulated pristine Bragg peak.
Spreading the Bragg peak to a width similar to that in our
experiment significantly lowers the peak to plateau-dose
ratio and hence the BEDR. We estimated this would reduce
the BEDR to 5. High uncertainties in this analysis have
prompted us to begin a comparison measurement for carbon
ions using a set-up equivalent to that at CERN.
Another important consideration in the comparison of
antiproton irradiation with other high-LET particles is the
value of the RBE upstream of the Bragg peak. As discussed
above, the RBE for antiprotons in the plateau region is not
expected to be different from that for protons. Because
the contribution of in-flight annihilation is small, the biolog-
ical dose deposited outside of the Bragg peak per particle is
essentially the same as that for a proton. This would have a
significant clinical advantage over other high LET particles
such as carbon ions, which have RBE values significantly
greater than 1 in the plateau region of the depth-dose
curve. As a consequence, it is not possible to use the clinical
experience with low-LET radiations to estimate normal tis-
sue tolerances without making an assumption for the RBE.
Because high-LET particles often have RBE values that are
energy, dose and cell type specific, one must use caution
in the application of these particles in the clinic. For anti-
protons, because the annihilation dose (high-LET compo-
nent) would be confined to the tumor, it would be
possible to treat using established normal tissue dose
tolerances.Peripheral damage
An important aspect for any new irradiation concerns the
biological consequences of dose that may be deposited out-
side of the primary beam. Initial attempts to assess periph-
eral damage caused by antiproton annihilation suggest it is
quite small. Even for the highest dose used in our experi-
ments, which resulted in a surviving fraction of 20% in the
plateau, we observed 55% survival at only 2 mm distal to
the Bragg peak (see Fig. 3). Furthermore, we also made pre-
liminary measurements of clonogenic survival in sample
tubes placed perpendicular to the beam at the Bragg peak.
These data also indicate that the peripheral dose is small
(data not shown). Further experimental studies in the
peripheral regions using beams with peaks spread according
M.H. Holzscheiter et al. / Radiotherapy and Oncology 81 (2006) 233–242 241to clinically relevant criteria will be required to fully quan-
tify these effects.Conclusion
In conclusion, our experiment has produced the first di-
rect measurements of the biological consequences of anti-
proton irradiation. It substantiates theoretical predictions
and earlier speculations on the consequences of antiproton
annihilation within the Bragg peak [15,25]. For the beams
compared in our study, the BEDR for antiprotons was 3.75-
fold larger than the BEDR for protons, which represents a
substantial increase in effective dose within the SOBP. In
a treatment situation, a higher energy beam with a larger
SOBP would be required to treat tumors of a reasonable
size. As a result, the peak to plateau dose ratio for either
a proton or antiproton beam would be significantly reduced,
and the comparison would yield a value below the value ob-
served here. However, antiprotons would retain a signifi-
cant biological dose advantage due to the contribution of
both the annihilation dose and its high estimated RBE. In
this regard, it is important to note that there are a number
of treatment situations in which increases in tumor dose as
small as 10–20% can produce significant improvements in
outcome.
Future research has to show if the advantages of antipro-
tons in terms of (a) higher physical dose in the Bragg peak,
(b) the increased RBE confined to the Bragg peak and (c) the
real-time imaging capability will warrant their serious con-
sideration as an alternative modality for tumor irradiation.
At that time it will be necessary to analyze both the techni-
cal and financial problems posed by the antiproton produc-
tion process. While the actual treatment center will be
similar to a standard proton center, the production of anti-
protons requires accelerating protons to 20–30 GeV. With
current technology this requires a synchrotron of about
100–200 m in diameter. Production, capture, storage and
delivery of antiprotons will require a number of additional
accelerator rings. CERN currently produces a modest
amount of antiprotons that suffice for limited biological
studies. GSI is planning the construction of a high energy
addition to their existing facility which will make available
antiprotons useful for irradiation at greater depths at inten-
sities sufficient for standard irradiation times and realistic
tumor volumes [26]. This facility could theoretically be used
to further evaluate and develop antiproton treatment
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Abstract17
1 Introduction18
The basic idea in antiproton radiotherapy [1] is to utilize the energy from the19
antiproton-nucleus annihilation reactions. Antiprotons behave similar as pro-20
tons at high velocities, but when they slow down, they will be captured by a21
nucleus and annihilate on its surface. Hereby twice the rest mass of the proton22
mp is released (1,88 GeV). The probablity for photo-emission similar to that23
known from the postiron-electron annihilation is rather small. Instead, in av-24
erage 4-5 pi-mesons are created [2]. The photons observed from the antiproton25
annihilation arise primarily from pi0 decay, which has a lifetime in the order26
of 10−16 seconds. For antiproton-nuclei reactions, there is a & 85% probablil-27
ity that one or more antiprotons will strike the nucleus [3]. Those entering28
the nucleus will start an intranuclear cascade, knocking out light nuclei [4].29
When antiprotons enter a chemical compount, consisting of several materials,30
the majority of the annihilations will take place on high-Z materials [5], e.g. for31
polystyrene only 1% will annihilate on hydrogen and the rest on carbon. Thus,32
from antiproton annihilation on e.g. tissue, a particle spectrum is expected,33
featuring pions, neutrons, protons, deuterons, heavier nuclei and photons. A34
1
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few kaons may also be created [6, 7]. Most of the 1,88 GeV released is carried35
away by the long-ranging particles, but still roughly 30 MeV is beind deposited36
locally near the annihilation vertex [8]. Even though this sounds disappoint-37
ingly low [2, 8], this is still a doubleing of the peak dose at the end of the38
antiproton particle track, compared to protons. The loss of the primary beam39
due to in-ﬂight nuclear reactions is expected to be slighly more than protons,40
but still less than that of carbon ions [9]. One of the anticipated advantages41
of the antiproton beam modality compared to protons, Thus, when comparing42
to protons, the antiproton depth dose curve will look similar to the depth dose43
curve of protons, but with additional energy deposited in the Bragg-peak from44
the antiproton annihilation. Antiprotons travel have a slighly longer range than45
protons, due to the Barkas eﬀect. This eﬀect becomes signiﬁcant at energies46
below 300 keV, and will shift the peak no more than ∼ 1 µm downstream.47
The Barkas eﬀect was experimentally veryﬁed by [10].
48
Since 2002 the AD-4/ACE collaboration has worked on assesing the dosimet-49
ric and radiobiological properties of beams of antiprotons [11–15]. In radiother-50
apy, where increases of 10 to 20% in the target dose are considered important51
while sparing the strain on the normal tissue, this could provide a signiﬁcant52
enhancement of the therapeutic ratio. [OJ: does a reference exist for this?]
53
The biological eﬀect of the antiproton beam diﬀers from the depth dose54
deposition, as the annihilation process yields fragments with a higher Linear55
Energy Transfer (LET). This means an increased relative biological eﬀective-56
ness (RBE) in the peak region relative to the plateau region. The biological57
eﬀect of an antiproton beam was for the ﬁrst time measured by Holzscheiter58
et al. [13]. However the RBE in the peak was not measured, as the dosimetry59
in this region was complicated by both the mixed particle spectrum and the60
pulsed form of the antiproton beam. Dosimetry with Alanine, Thermolumines-61
cent devices and radiochromic ﬁlms were tried out, but these suﬀer from the62
LET dependence of the response. Calorimetric measurements were considered63
as too cumbersome. Ionisation chamber measurements were initially believed to64
be complicated due to the pulsed structure of the antiproton decelerator (AD)65
antiproton beam at CERN. Later it was realized that Boag’s theorem as de-66
scribed in [16] could be applied. Shortly, Boag’s theorem is determining the67
amount of volume recombination by measuring collected charge at two diﬀerent68




The antiproton decelerator at CERN is setup to provide a 502 MeV/c (∼125.8571
MeV) antiproton beam. Every 90 seconds a spill of roughly 3 · 107 antiprotons72
is ejected within 300 ns. The momentum spread of the beam was ∆p/p = 10−3,73
and the divergence is in the order of 5 mrad. The FWHM of the beam was74
slightly ellipsoid, being about 1 cm in one axis, and 0.9 cm along the other75
axis. The beam exited via a thin titanium window and was collimated to 1 cm76
diameter.77
The target phantom is a water tank build of PMMA material according to78
IAEA and ICRU standards for proton therapy [17, 18]. We used two ionization79
chambers of the Advanced Roos type chambers from PTW Freiburg. These80
have graphite electrodes and an active diameter of 39,6 mm. The ionization81
2
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chambers are calibrated with 60Co gamma-rays at +400 V towards a reference82
ionization chamber using the in-house gammatron at the DKFZ. The reference83
chamber is a PTW Roos ionization chamber M34001 and is calibrated at PTW,84
being a SSDL secondary standard dosimeter laboratory.
85
At the antiproton beam line at CERN, one ionization chamber is attached86
before the entrance window to the water phantom. This chamber is solely used87
for normalization of the shot to shot ﬂuctuations of the antiproton beam. The88
second chamber is attached to a calliper which provides submillimeter precision89
readings of the ionization chamber position. The collected charge is read out90
with a UNIDOS electrometer.91
At each caliper position, data from each shot of antiprotons were recorded.92
The ﬁxed ionization chamber at the entrance window is kept at +400 V at all93
times. With the ionization chamber mounted on the water phantom we usually94
record 4-8 shots at +400 V and 4 shots at +300 V. The electrometer is read out95
and reset after each shot. At three caliper positions, the entire voltage range96
from the UNIDOS electrometer is investigated in 50 V steps.
97
From the measured charge q1 and q2 recorded at V1 = 400 V and V2 = 300,98






ln(1 + u1V )
(1)
where q = q1/q2 and V = V1/V2. Equation 1 is derived from equation 9 in100




ln(1 + u1) (2)
In practice, a program was written, which uses the root ﬁnding algorithm102
provided by the Gnu Scientiﬁc Library [19]. As a input parameter the measured103
charges at two voltages are needed. The program then outputs the collection104
eﬃciency f1.105
At some caliper positions, we only measure charge at one voltage setting (400106
V). Here the charge collection eﬃciency is interpolated. Beyond the annihilation107
peak the acquired charge was small and equation 1 has no solution due to108
statistical ﬂuctuations, and instead the correction eﬃciency is extrapolated.
109
The absolute dose DQ of the antiproton beam quality Q can then be found110
using the Boag’s corrected collected charge MQ,B :111
DQ = MQ,BNQ0kQ,Q0 (3)
where NQ0 is the
60Co calibration factor. kQ,Q0 is the chamber speciﬁc correc-112
tion factor, but here it was set to 1. For proton beams this factor is expected113
to be similar to that of the Roos chamber which according to [17] is expected114
to lie between 1.001 and 1.008.115
3 Monte Carlo Calculations116
For comparison calculations, both FLUKA v. 2006.3 and SHIELD-HIT v2.2 are117
used. The geometry applied in FLUKA and SHIELD-HIT consist simply of a118
502 MeV/c antiproton beam hitting a 20x20x20 cm water tank. The Gaussian119
3
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beam was set to have a FWHM of 1.0 cm and 0.9 cm along x and y axis. In120
FLUKA the statistics are 150.000 particles. In SHIELD-HIT 100.000 primary121
particles are simulated.
122
The scoring region is a stack of discs placed along the beam axis. Each disk123
is 1 mm thick and a has a diameter of 39,6 mm, matching the eﬀective diameter124
of the ionization chamber. Since the FWHM of the beam is only in the order125
of 1 cm, practically all antiprotons are contained in the active scoring region.
126
For comparison with protons, the FLUKA calculation was repeated using127
a 5x5 cm square ﬁeld of antiprotons, maintaining the other beam parameters.128
The average dose is scored along the beam axis using ﬂat discs with radius 0.5129
cm and a thickness of 0.25 mm. Here 300.000 particles are simulated.
130
4 Results131
The measured depth dose curve compared with SHIELD-HIT and FLUKA are132
shown in ﬁgures 1 and 2, respectively. The charge correction eﬃciency which133
was applied is shown in ﬁgure 3.
134
The results are here plateau normalized at a depth of 60 mm in order for135
better showing the deviations in the form of the depth dose curve. The SHIELD-136
HIT calculations show a deviation of almost 20% in the peak region, whereas137
FLUKA seem to match the measured depth dose curve very well.
138
Figure 1: SHIELD-HIT v.2.2 results compared with CERN measurements.
In terms of absolute measurements, our measurements indicated higher doses139
than calculated with SHIELD-HIT or FLUKA. For each antiproton we measure140
on average 0,64 ± 0,03 MeV/g deposited dose in the ﬁrst ionization chamber.141
Here we assume the same 2% correction from Boag’s theorem, as calculated in142
the second ionization chamber located at position “0 cm”. The “0 cm” posi-143
tion corresponds to ∼ 2, 8 cm of water equivalent material (from the ionization144
4
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Figure 2: FLUKA 2006.3 results compared with CERN measurements.
Figure 3: Calculated charge collection eﬃciency.
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chamber thickness and entry window), and was used as a reference point for all145
measurements.146
For the second ionization chamber we see 0,72 ± 0,01 MeV/g of deposited147
dose in the “0 cm” position, and 1,04 ± 0,02 MeV/g at the “60 cm” position. In148
table 1 below we compare these values to the those calculated by SHIELD-HIT149
and FLUKA. The errors stated here are 1σ standard deviations.150
SHIELD-HIT FLUKA Measurements
[MeV/g] [MeV/g] [MeV/g]
Entry chamber 0,54 0,60 0,64 ± 0,03
Chamber @ “0 cm” 0,59 0,68 0,72 ± 0,01
Chamber @ “60 cm” 0,93 0,95 1,04 ± 0,02
Table 1: Absolute comparison of deposited dose.
A ﬁeld of antiprotons compared to that of protons is shown in ﬁgure 4.




















Figure 4: Comparison of depth dose curves from a pristine antiproton beam
with a similar proton beam.
151
5 Discussion152
We found excellent agreement between ionization chamber and FLUKA data for153
relative dose and reasonable agreement in the plateau regions for absolute dose154
(Error < 6-9%). The origin of the systematic deviation is not clear, but may155
be possibly be attributed to two sources: First, the Advanced Roos chamber156
calibration was calibrated towards another ionization chamber which has an157
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uncertainty of ±4%. Second, the calibration of the beam pickup is good to158
±1%.159
After veriﬁcation of FLUKA, this will possibly allow us to extract RBE160
values from the measurements presented in [13] and future measurements carried161
out at CERN.162
In addition, this will give more credit to the proton - antiproton comparison163
presented in ﬁgure 4. Here we used a broad beam shape in order to more closely164
match a clinical situation. In principle this beam could be made passively or165
actively to cover the entire 5x5 cm area. Scoring the central dose region, several166
features can be observed. In the entry region, a slight elevation of the dose level167
is seen as compared to protons, arising antiprotons annihilating in-ﬂight. The168
peak region itself is augmented with over 220% as compared with the proton169
Bragg-peak, at iso-ﬂuence.
170
Finally, the diﬀerent results from SHIELD-HIT is most likely related to dif-171
ferent in-ﬂight annihilation cross-sections. The amount of in-ﬂight annihilation172
cross sections is discussed in [9].
173
[insert philosophical discussion about antiprotons here]
174
6 Conclusion175
Simulations with FLUKA 2006.3 are in excelent agreement with our relative176
measurements. In terms of absolute dose, our measurements are 6-9% higher177
than the FLUKA calculations, but this may be attributed to a beam pickup178
calibration. SHIELD-HIT v.2.2 overestimated the peak - plateau ratio, which179
is attributed to the internally used annihilation cross sections.
180
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Appendix D: Submitted to Radiation Research
1 Abstract
In this paper we report on the measurement of the antiproton depth dose curve, with alanine detectors. The
results are compared with simulations using the particle energy spectrum calculated by FLUKA, and using
the track structure model of Hansen et Olsen for conversion of calculated dose into response. A good
agreement was observed between the measured and calculated relative effectiveness although a slight
underestimation of the calculated values in the
Bragg peak remains unexplained. The model prediction of response of alanine towards heavy charged
particles encourages future use of the alanine detectors for dosimetry of mixed radiation fields.
2 Introduction
Antiproton radiotherapy was first suggested by Gray and Kalogeropoulos in 1984 [1]. One of the
anticipated advantages of antiprotons compared to protons, is the additional energy deposited at  the Bragg-
peak from the antiproton annihilation. Sullivan suggested in [2] that the additional local energy deposited
by the annihilation products may roughly be about 30 MeV. Even though this value sounds low compared
with the total of 1.88 GeV released by the annihilation, this still results in a substantial augmentation of the
peak dose at the end of the particle track.
To interpret a measured response of a biological system exposed to a beam of hadrons in terms of dose
deposition, a prediction of the Relative Biological Effectiveness (RBE) for the particular beam of particles
is necessary. Similarly, for a radiation detector the relative effectiveness (RE) is relating the observed
detector response with dose deposition. The observed response of a detector is here expressed in terms of
the dose R, which is the dose as read from the gamma
response curve. This term will exclusively be used here to express response. For the dose Dion deposited by
ions, we have
ionion DRER ⋅= (1)
Thus, Rion is the response of a detector exposed to ion beams expressed in terms of the dose by _-rays,
neccessary to produce equal response. Here, “ion” means any particle with Z ≥ 1. Note, that often the term
Heavy Charged Particles (HCPs) is used, referring to particles with Z > 1.
For a given biological system and chosen endpoint, RBE is a function of the target parameters, atomic
number and velocity of the bombarding particle, why the biological effect per unit dose changes with the
penetration depth of the particle. Thus the RBE in the plateau region is different from that in the Bragg-
peak. The difference of plateau and peak RBE increases significantly with atomic number of the projectile.
For protons one generally assumes an RBE close to unity for the entire penetration, even though an
increase of RBE beyond this value has been observed for the distal edge of the Bragg peak [3, 4].
For HCPs the increase of RBE with depth becomes more pronounced and also shifts towards the entrance
to the target with increasing atomic number. For antiprotons compared to protons of the same energy, the
difference in RBE is further enhanced in the peak region, due to the annihilation process which also yields
fragments with Z > 1. In the plateau region, antiprotons are expected to behave similar as protons.
Attempts to measure the RBE directly in the peak region so far have failed, since dosimetry of the
antiproton depth dose curve is problematic due to the unknown dosimeter response [5–7]. Ionization
chambers behave non-linear too, due to volume recombination [8] arising from the pulsed nature of the
antiproton beam available at CERN. Measurements using Boag’s theorem [9] correcting for recombination
effects have been performed and a publication on this is in preparation. Calorimetry is the most direct way
to measure absorbed dose according to its definition. However, calorimeters are cumbersome to use and are
not easily applicable in a low-frequency pulsed beam such as CERN’s antiproton beam. Other detectors we
have applied in the antiproton beam are Thermoluminescent Devices (LiF based) and radiochromic films
[10]. This paper, however, will concentrate on the results achieved with alanine detectors.
The response of alanine detectors to HCPs was investigated by Hansen and Olsen in the 80’s [11, 12]. A
model explaining the behaviour based upon the Butts and Katz track structure idea [13, 14] was conceived
[15]. This model has had some success in predicting the RE of alanine detectors, including fading effects:
most solid state radiation detectors show a post-irradiation time dependent change in response when
exposed to saturation doses, a phenomenon being of importance in the evaluation of dose-response for
detectors exposed to beams of HCPs. Though alanine has been reported to have a high time stability of
radiation induced response to gamma rays of doses less than 104 Gy, considerable decay has been observed
after low average doses from heavy charged particles. The amount of decay has been found as well to be
dependent on the ion parameters [16], more precisely, on the radial dose distribution around the particle
track. Predictions based on the model of track structure have shown to conform to experimental data [12].
Then due to the higher atomic number annihilation fragments in the Bragg peak of antiprotons the fading
processes will be more pronounced and should from a theoretical point of view be taken into account when
comparing the radiation effect in the Bragg peak with that
of protons.
The decay in alanine is dominant within the first 100 to 200 hours after exposure to HCPs, and the rate of
decay is different for pellets positioned in the plateau compared to those in the Bragg-peak [16]. E.g. a 250
MeV/u carbon ion fades 1.6% after 1900 hours. At 1 MeV the fading approaches 5 %. When irradiated
with 250 and 1 MeV protons the response fades 1.6% and 2.3% after 1900 hours.
Here we shall apply the track structure model on a mixed particle energy spectrum simulated by FLUKA,
in order to calculate the RE and then the expected response of alanine pellets based on the measured
gamma-ray dose-response curve. The predicted response as a function of penetration depth is compared to
that measured from a stack of alanine pellets exposed to a beam of antiprotons.
3 Experimental Methods
Two stacks of alanine pellets were irradiated with antiprotons. The pellets in stack #1 consisted of finely
grained crystalline alanine powder (Merck) 95% by weight mixed with 5% by weight polyvinyl-
pyrrolidone (Polyvidone, Merck) as the binding agent and were manufactured by J.W. Hansen. The pellets
had an outer diameter of 4.5 mm, a thickness of 2 mm, and a density of 1.21 g cm-3. Details about the
dosimeter pellets have been published [15]. In this stack seven pellets were placed in the plateau, and 18
pellets were placed around the annihilation peak.
Stack #2 consisted of alanine pellets which were produced by NPL and constituted of 90% by weight L-_-
alanine and 10% high melting point paraffin wax. The diameter of the pellets was 5 mm and the thickness
was either 2.2 mm or 0.44 mm (average values for the entire batch). The average density was 1.24 g cm-3.
The stack was assembled from eleven 2.2 mm pellets, six 0.44 mm pellets and five 2.2 mm pellets,
arranged in a 5.2 mm cylindrical hole in a PMMA phantom. A build-up plate of 81.8 mm polystyrene was
used in order to position the Bragg peak around the position of the thin pellets.
The Antiproton Decelerator (AD) at CERN provided a 502 MeV/c (~126 MeV) antiproton beam. Every 90
seconds a spill consisting of roughly 3 · 107 antiprotons was ejected within 300 ns. The momentum spread
of the beam was _p/p = 10-3, and the divergence in the order of 5 mrad. The absolute number of particles
extracted from the AD was determined by a fast current transformer mounted downstream of the extraction
septum in the DEM beam line, feeding our experimental set-up. Earlier studies showed that this number
may have a tendency to overestimate the fluence at the target by 10 - 20%. This may be due to calibration
errors and/or to losses in the final stretches of the beam line leading up to our set-up. The beam exited the
accelerator vacuum via a thin titanium window and was collimated to 1 cm diameter.
The alignment of the two stacks was verified with two radiochromic films (GAFChromic) which were
inserted along the beam. The FWHM of the beam when irradiating stack #2 was almost circular with a
FWHM of 0.9 - 1.0 cm. The beam which was used for stack #1 had a more ellipsoid form of roughly 0.6 -
1.0 cm FWHM. Stack #1 was read out by the Radiation Research Department at the Risø National
Laboratory in Denmark, using a Bruker EMS 104 EPR alanine readout device. Stack #1 was read out
several times at increasing time intervals, in order to detect any fading effects, as reported in [16]. At each
readout, the pellet was measured at zero and 90°? rotation and a mean signal strength was obtained. Stack #2
was read out at the National Physics Laboratory (NPL) in the UK using the standard procedures for NPL’s
radiotherapy level alanine dosimetry service [17]. The spectrometer was a Bruker ESX and a standard
Bruker ST4102 rectangular cavity. The acquisition time was 120 s consisting of six 20 s scans with 90°
rotation of the pellet between the third and fourth scan. The pellets were introduced in the spectrometer
using an automated loading system with a specially constructed sample holder to provide highly accurate
positioning [18].
4 Monte Carlo Calculations
FLUKA [19, 20] version 2006.3 was used for calculating the antiproton particle transport through the
medium, and the distribution of secondaries in each alanine pellet. The beam profiles measured with the
radiochromic films was used as input parameter for FLUKA for stack #1 and stack #2. For example for
stack #1 a little misalignment of 2 mm and a rotation of the phantom of a few degrees was applied. 100.000
particles were used for the statistics. The dose D from all particles (including contribution from gamma-
rays) was scored in every pellet position. In addition, the track length fluence-energy spectrum _[Ej,Zi] for
pions, protons, deuterium, tritons, He-3 and He-4 was recorded for each pellet using the USRTRK card in
FLUKA. _[Ej,Zi] is thus a matrix divided in particle types Zi and energy bins with the mean energy Ej.
Since π+ and π-?both have unity charge, charged pions are treated as protons with A = 0.15 amu. π0 particles
are neglected as they decay instantaneously into gamma rays. Antiprotons are treated as protons.
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dE
ρ
is the mass stopping power for particle Zi at energy Ej .
The stopping power is evaluated at the center of the energy bin using the PSTAR and ASTAR routines by
Berger et al. [21]. MSTAR (by Paul and Shinner [22,23]) support is included in the data reduction program,
but was not used, as nuclei with Z > 2 were ignored. The dose DTL calculated by the track length fluence, is
lower than the FLUKA dose D, since photons and particles heavier than He-4 are not included in the DTL
calculation. The difference is usually
about 1-2% in the plateau region and about 7% in the pellet(s) covering the peak region.
From the track length fluence matrix _[Ej,Zi] the relative effectiveness of each particle-energy entry is
looked up in a table. This RE table is generated using the model by Hansen and Olsen for infinitesimal thin
detectors. By summing all individual detector responses Rion(Ej ,Zi) = RE(Ej,Zi)D(Ej,Zi) for each energy bin
Ej and particle type Zi, a total dose weighted average relative


















The calculated RE multiplied with the total dose D (now including all fragments) for the pellet scored by
FLUKA in combination with the measured _-ray dose-response curve gives the predicted response of the




In the figures 1 and 2 below, the total measured response of the alanine pellets as a function of penetration
depth is plotted together with the response calculations and the predicted dose for stack #1 and #2
respectively. Fading effects were included in these calculations. The response is expressed in terms of
response equivalent gamma dose.
All measurements are absolute, as the total number of antiprotons were measured upstream the beam with
the beam current transformer. This may introduce a systematic error, as some of the beam may be lost on
the way from the transformer to the experimental setup, as mentioned earlier. For stack #1 in figure 1 the
measurements have been shifted by 1.5 mm along the beam axis, in order to match the peaks (see below).
The fading of the alanine tablets was investigated with alanine stack #1. Unfortunately the ESR-
spectrometer for these readings turned out to be very unstable resulting in unreliable measurements for
which fading could not be determined with a sufficient accuracy. From calculated predictions we expect to
find a difference of approx. 1% in fading between dosimeters positioned at the plateau and in the peak.
Most of this fading in response is considered to take place within 200 hours after irradiation. Here we
applied 800 hours for the stack #1 and 1900 hours for stack #2, but the fading effects are too small to be
observable.
[figure1: johnny_pub.eps]
Figure 1: Stack #1 results. The dotted line shows the dose for each pellet as it is calculated by FLUKA. The
calculated dose multiplied with the calculated relative effectiveness is plotted as a solid line, and should
ideally match the measurements marked as unconnected squares. Measured response is translated to dose
using the _-ray dose-response curve.
[figure2: hugo_pub.eps ]
Figure 2: Results for stack #2 plotted in the same fashion as figure 1. The measurements were not shifted
along the x-axis, though.
Using equation 3 the calculated relative effectiveness as a function of the particle penetration depth for
stack #2 is shown in figure 3.
[figure3: eta.eps ]
Figure 3: Calculated relative effectiveness for stack #2. The relative effectiveness drops off in the peak
region due to the the slowing down of antiprotons and the annihilation products with higher LET.
6 Discussion
One of the major differences between stack #1 and #2, was the fitting of the pellet diameter to the ∅5 mm
hole drilled into the phantom. The stack #1 leaved a gap in between the pellet and the cavity wall whereas
the stack #2 pellets did fit the hole exactly. The presence of this gap enables some antiprotons to tunnel past
the pellets. Furthermore, the pellets in stack #1 did not have a
perfect cylindrical form, but had a little edge at the rim of the outer diameter. This will increase the amount
of range straggling of the antiproton beam, thus widening the peak, and localizing it further downstream the
beam axis. This may possibly explain the shift of 1.5 mm downstream from the predicted position of the
measured peak. This effect is thought to be much less pronounced for stack #2, as these pellets had perfect
cylindrical form which closely matched
the phantom cavity.
Another difference between both stacks was the density matching of the pellets and the surrounding
phantom. For stack #1 the alanine pellets had 1.21 g cm-3 and were surrounded by polystyrene with 1.04 g
cm-3. For stack #2 the 1.24 g cm-3 pellets were surrounded by a PMMA phantom with a density of 1.19 g
cm-3. This effect is responsible for the difference in the shape of the tail since antiprotons can penetrate
deeper in the surrounding phantom as in the alanine stack and their annihilation can contribute dose beyond
the Bragg peak.
Both stacks provide absolute dose measurements. Since the plateau region of the stack #2 fits the
calculations very well, the systematic effect of a possible overestimate of the recorded particle fluence due
to the upstream position of the beam current transformer seems to be minor. Absolute dose measurements
for stack #1 are more problematic, since the alanine readout device had a tendency to drift.
The RE is fairly close to unity in the plateau region, and drops down to about 0.8 in the peak region. The
reason for this rather slight change in RE is due to the low atomic number of the antiproton itself but also
due to the resulting mixed field of relative light nuclei from the antiproton annihilation. According to
Polster et al. [24] the field in the peak region consists mostly of relative light nuclei of high energy, which
is also what we see in our FLUKA calculations. Those fragments have fairly high REs due to the high
energies of the secondary particles, compared to that of stopping antiprotons.
The nature of the slight overestimation of the calculated dose maximum in the annihilation peak is rather
unclear. Several possible explanations exist:
• the RE model has shown [12] to be only partially correct for HCP-energies below 2 MeV/u
• errors in the geometry used as input parameter for the FLUKA calculations
• omission of Z > 2 particles in DTL and the RE calculation in equations 2 and 3
• limitation of the inherent model in the FLUKA code to predict the annihilation peak accurately
On the experimental side a source of error may be the fact that the pellets consists of grains in a matrix
whereas the Monte Carlo simulations assume a homogeneous mixture. Finally, the local shape of the
annihilation peak is very sensitive to volume averaging effects, which may not be reproduced accurately in
the Monte Carlo simulation. In the end, we can state that alanine together with model calculations of RE is
a perfect dosimeter in mixed radiation fields as former shown for neutrons [25].
Models based on track structure theory by Katz, and derivatives of the Local Effect Model such as ECLaT
[26] for Thermoluminescent Devices (TLDs), rely on predicting the response of a detector from the
gamma-response curve which is convoluted with the radial dose distribution of a track in order to achieve
the relative effectiveness of the HCP radiation in question.
Here, the response calculations are further simplified since interactions between two or multiple tracks
were not considered. The inclusion of track interactions in the RE-calculation would lead to a lower
predicted RE and thus to less calculated response. Track interactions are most likely to happen at high
fluences where the mean track distance 1−ϕ  becomes similar to that part of
the track radius in which ”cross-overs” would lead to saturation response. The neglect of track interactions
in the calculation of effectiveness is most likely possible due to the high saturation dose of alanine. The
region of saturation in a single particle track is smaller in a detector with a high saturation level, i.e. low
radiation sensitivity, than that of a detector with a low saturation level, i.e. high radiation sensitivity.
Therefore the effect of overlapping tracks is expected to be low for the alanine detector.
7 Conclusion
In this paper we have used alanine detectors for the dosimetry of the mixed particle field arising from
antiproton annihilation. We believe that Alanine is very suitable for this kind of dosimetry. The antiproton
depth dose curve was measured with alanine pellets. The results could be reproduced using the relative
effectiveness calculated with Hansen’s and Olsen’s track structure model used in conjunction with doses
and particle spectra calculated with FLUKA. The alanine detector is a good detector for characterizing the
mixed radiation field from antiproton annihilation. This detector could also be applied for dosimetry of
medical heavy ion beams and possibly in mixed radiation fields found in space.
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